Latest innovations in molecular biology, genetics and cell biology have
revolutionized the understanding of disease parthenogenesis and efforts
related to discovery of novel disease biomarkers and drug targets,
eventually leading to development of more effective medication with
fewer side effects. A special focus of these cutting-edge approaches has
been the field of leukemia and other blood cancers with discovery of
many new cancer-causing genes and therapies directly targeting cancer
cells and oncogenes. Acute Myeloid Leukemia (AML) has undergone major
innovations in terms of early diagnosis, molecular sub-classification of
the disease, prognostic stratification and new drug discovery,
culminating into patient-tailored treatment of AML patients. This books
provides an account of the biology and account of genetic basis of AML
and their implication in clinic and research.